In developed countries, all NSCLC patients, regardless of their clinical characteristics, are routinely tested for suspected mutation points, such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) fusions, ROS proto-oncogene 1 (ROS1) fusions, and N-methyl-N′-nitroso-guanidine human osteosarcoma transforming gene (MET) mutation and amplification [5,6]. Here, ALK is linked to non-small cell lung carcinoma.